D-Cycloserine for Serine Palmitoyltransferase Inhibition

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT07542548
Phase
PHASE4
Status
Completed

Conditions

  • Hereditary Spastic Paraplegia

Eligibility Criteria

Sex
FEMALE
Age
6 Years - 6 Years
Healthy Volunteers
Not accepted

Interventions

  • D-cycloserine — DRUG
    Pyridoxine also prescribed to help prevent neurologic adverse events related to D-Cycloserine.

Study Details

The overarching objective of this study is to mitigate the neurological decline associated with SPTSSA related Complex Hereditary Spastic Paraplegia

Key Dates

Start date
Jul 10, 2024
Status verified
Apr 2026
Primary completion
Mar 17, 2026
Completion
Mar 17, 2026

Study Design

Enrollment
1 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: D-Cycloserine
    D-Cycloserine Administered for Complex Hereditary Spastic Paraplegia

Primary Outcome Measure

Frequency of treatment related serious adverse event [ Time Frame: From baseline to the end of treatment at 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02114-

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital· Boston, MA

Related Studies